Rituximab Dosing in Myasthenia Gravis
For adults with refractory myasthenia gravis, administer rituximab 1000 mg on day 1 and day 15 (two weeks apart), which represents the most commonly used and evidence-supported regimen, though emerging data suggests lower doses may be equally effective with better safety profiles.
Dosing Regimens
The evidence reveals two main dosing approaches, both supported by clinical data:
Standard Rheumatology Protocol
- 1000 mg IV on day 1 and day 15 (two weeks apart) 1
- This mirrors the dosing used for rheumatoid arthritis and ANCA-associated vasculitis 2
- Most established in the literature for myasthenia gravis
Alternative Lymphoma Protocol
- 375 mg/m² IV weekly for 4 weeks 1, 2
- Derived from non-Hodgkin's lymphoma treatment protocols
- Appears clinically equivalent to the rheumatology protocol 3
Emerging Low-Dose Approach
Recent research suggests significantly lower doses may be equally or more effective:
- Single 500-600 mg infusion with CD19+ B-cell monitoring 4
- 100 mg weekly induction (up to 3 cycles) followed by 100 mg reinfusions based on CD19+ B-cell repopulation 5
- Meta-analysis shows low-dose regimens achieve 76.6% MMS or better vs 51.6% with conventional doses 6
Clinical Decision Algorithm
Choose standard dose (1000 mg × 2) if:
- Severe, refractory disease requiring aggressive treatment
- MuSK-antibody positive MG (though responds to any dose)
- Access to infusion center is limited (fewer visits)
Consider low-dose approach (500-600 mg single or 100 mg serial) if:
- New-onset or early generalized MG 5, 7
- Mild-to-moderate disease severity
- Concern for infection risk or hypogammaglobulinemia
- Cost is a significant factor
- Ability to monitor CD19+ B-cell counts regularly
Pre-Treatment Requirements
Before administering rituximab 1:
- Baseline immunoglobulin levels (IgG, IgM, IgA)
- Hepatitis B and C antibody screening
- Latent tuberculosis screening
- Premedication: Methylprednisolone 100 mg IV (or equivalent glucocorticoid) 30 minutes prior to each infusion
Maintenance and Reinfusion Strategy
CD19+ B-cell guided approach (preferred for individualized care):
- Monitor CD19+ B-cells every 3 months 5, 8
- Reinfuse when CD19+ B-cells ≥1% of total lymphocytes AND clinical symptoms worsen
- Typical reinfusion dose: 100-500 mg single infusion
Fixed schedule approach:
Expected Outcomes
Efficacy timeline:
- Clinical improvement typically begins 2-6 months post-treatment 5, 6, 10
- 59% overall achieve minimal manifestation status or better 6
- MuSK-positive patients respond better than AChR-positive (66.7% vs 33.3% success at 60 months) 11
- Steroid-sparing effect: 76-90% reduce to ≤10 mg/day prednisone within 6-12 months 8, 11
Critical Safety Considerations
Monitor for:
- Progressive multifocal leukoencephalopathy (PML) - rare but fatal 1, 12
- Severe infections requiring treatment discontinuation
- Hypogammaglobulinemia with repeated dosing 8
- Infusion reactions (premedicate appropriately)
Common pitfall: Do not use rituximab as first-line therapy in newly diagnosed MG unless patient is steroid-intolerant or has contraindications to conventional immunosuppression. The evidence supports its use primarily in refractory cases 10, 13, though emerging data suggests earlier use may be beneficial in selected patients 5, 7.
Important caveat: The optimal dosing remains uncertain. While conventional doses (1000 mg × 2) have the longest track record, accumulating evidence suggests lower doses may provide equal or superior efficacy with better safety profiles 5, 6, 4. The choice should balance disease severity, antibody subtype (MuSK vs AChR), treatment refractoriness, and monitoring capabilities.